Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Expecting 300% gains from here by the end of 2016. The markets largely over-reacted creating a great buying opportunity and a relatively safe play here.
We should see the phase 1 efficiency and safety numbers for Ebola vaccine (INO-4212 SynCon)in Feb - March 2016, an additional cancer DNA vaccine announcement sometime mid year 2016 and then speculating MERS vaccine numbers possibly out by years end.
These are the only near-term catalyst I foresee other than a buyout. And Inovio is well positioned for a buyout!
Dragging the share price down will be the cost of INO-3112 (VGX-3100/INO-9012) Phase III trial. Although they have an excellent balance sheet today; I imagine the company will have to raise additional capital through dilution. Additionally the 4th qtr 2015 numbers will bring down share price down due to the contrasting decline in revenue versus current 3rd qtr numbers.
I have only a small stake here but Inovio as DNA-based infections disease small cap appears well managed and positioned for success.
The infectious disease portfolio has largest upside to me. DNA based vaccines are pretty cool and exciting. the company leverages partnerships well and DARPA seems to think highly of these guys too. Inovio seems really far away from making any noise in cancer immunotherapy. They're many other companies well ahead of Inovio in this field.
I plan on trading through these waves and will be in and out of this stock. As a whole the company appears a few years away from having a flagship product but has great potential.
Frank Curzio had Ross Beaty on his podcast Aug 12th. I thought it was an informative interview and gives some great insight on current Alterra projects.
It was 6-12 months. So it will be the beginning of next year.
Hit 7.17. See if it continues up tomorrow too
A lot of red in my portfolio today. NW being the only bright spot and for the next few trading days.
There many positives to be taken from today's and yesterday's pr's. For one; even though no numbers but alluded they will follow near term, the significance of the statement "substantial tumor necrosis and initial tumor regression" is off the charts big big news. Ground breaking. To see other bio therapeutic companies following NW lead with similar innovations shows the viability of immunotherapy.
Very exciting stuff. FDA approval of Direct and L will happen.
Up 71 cents pre-market over 130K shares. Going to be a great day!!
No. The data appears recent as it is updated monthly. 3 centers finished recruitment with one center finished trial.
I misunderstood the context at first
Active, not recruiting:
New York University Clinical Cancer Center
Overlook Hospital
Cleveland Clinic Foundation
Completed:
Georgetown University Medical Center
Overall not impressive but provides a measure
Found this was interesting.
Taken from the ClinicalTrials.gov the DCVax-L (NCT00045968) trial was updated by NW on 4/18/2014 as an active trial no longer recruiting. You need to dig into the changes made as it fails to show on the title page.
Amen afford
The valuation is a personal opinion but while most people here over analyse this company I would want to remind you its really about the science of which I've followed ... wow um since 2004-2005? where I find the valuation potential of billions dollar market cap.
I don't pretend to understand the intricacies of the science itself but I can certainly relate to the numerous unsolicited testimonies given over the years.
IMO, the near future milestones we will see for this company is DCVax direct announcements at ASCO on the FDA's "breakthrough therapy designation", its trial data then DCVax L early fall.
From an investor stand point, this price is cheap. And I've owned it since it was .16 cents a share. I made over 100k in DNDN and that was just 1 mildly effective $90K product. This company was never well run or given much mind to appeasing investors, but the science is sound, they have always progressed, hit their marks, and they are without sensationalism (ASCO is way outta character!). Investments like this don't always make themselves so evident. To me this is a no-brainer. This is going to be epic.
Look forward to buying up more asap. great buy price
I believe what we will hear announced at ASCO from NW in a few weeks will be about DCVax Direct and the FDA acceptance of DCVax Direct into the FDA breakthrough therapy designation and its 60 patient proof of concept Phase I/II. This will allow the simple transition to Phase II with each efficacy seen among the 6 patients of each cancer group along with cutting years of approval.
From FDA.gov
* A clinical trial for a drug that has been designated as a breakthrough therapy generally has to enroll fewer patients prior to approval.
* FDA will work closely with sponsors to ensure that the design of the clinical trials is as efficient as practicable, when scientifically appropriate. An efficient trial design typically would help minimize the number of patients exposed to a potentially less efficacioustreatment, which could translate to fewer patients enrolled in clinical trials that support marketing approval. Regulatory standards to demonstrate safety and efficacy must still be met.
* The FDA will not disclose information regarding sponsors who submitted requests for or who have been granted or denied breakthrough therapy designation. Breakthrough therapy designation requests are typically submitted to an IND, and the FDA cannot disclose the existence of an IND, or any submissions that have been submitted to the IND, unless it has previously been publicly disclosed or acknowledged per 21 CFR 312.130(a).
Linda in the last speech punctuated the fact that the company was working closely with the FDA and ASCO acceptance of the abstract announcement.
I did my best earlier to summarize the webcast #7327
There two big items for me personally given out.
My take-away is they would like to be a part of the trail because of its success and expand patient availability. She stated the term in response to irresponsible blogging and "if the trial was going badly why would these centers of excellence want to join"
The reason for expanding the trial was spun to the fact of more organizations for healthcare excellence want to join.
Not exact words but was how I perceived it.
Appears nothing news breaking coming out.
*Although she's emphasized the difficulty with Germany and getting the hospital exemption.
*The 6 hospital re-imbursement.
*Expanding on the fact they now have the ability to treat more than one patient at a time i.e. compassionate use only affords a single patient under care at a time
*Re-iterated DCVax-L data shows 6 weeks SOC chemotherapy vs. immunotherapy at least 2 years of qol with 2 patients over 10 yrs.
*Pointed out the trials design for phase 3 is on a continue, continuing on-track, no negatives sighted, and expanding the trial, dates scheduled in May/June for "centers of excellence" to join the trail
*DCVax Direct trial covers all types of cancers, and is not specific to one particular cancer type.
*ASCO has accepted the abstract and cannot discuss data between now and then when a major announcement will be presented.
Interesting. Linda stated the time to create a vaccine is down to 5 days versus 5 months it took previously.
Webcast started!!
Appears the agenda was made weeks ago. Not sure how relevant if this is breaking news.. if
An excellent "reality check"
It would be amazing for the company to present a major milestone within the companies existence today but the reality is a webcast has been given every month since December. No this would not be out of the ordinary.
Being most everyone here likes to analyze every word coming out of the company... "A Long-Awaited Reality" conference is exciting.
I "have an appointment" and left work early..
Relatively easy to signup. It also host a social stream. So we'll be able to see the chatter.
http://nwbio.com/webcasts/
I wonder how many traders will have be logged into their trade accounts ready to sell in the event nothing ground breaking is presented.
So whos scheduling their day around the webcast??
$7.24 up .31 / After Hours Volume:2,015
It appears investors have sold shares for warrants to the point share price is slighly more than double the cost of a warrant. Warrant price has risen while pps of NWBO as declined over the last few trading days. Although a warrant can typically be good way to limit loss within a medical/FDA trial share price will more closely follow trial progression and treatment potential. If something unforeseen delays a trial timeline a warrant can stagnate just as options do, and expire worthless. We can have FDA hold ups that take years to mitigate. Moreover, warrants will always suffer more with ANY bad news such as dilution and overall they provide a much lower level of liquidity.
Everything is progressing and so I have picked up more shares. I dont see much benifit in this particular situation to purchase warrants. Buy a 1.50 warrant when I can buy a share at 3.30? Keeping it simple here. The science is good and appears to work. And without toxicity? What is going to stop approval? Its not brain surgery. Investors talk about getting to a best case scenario of a $10 pps here? I'm looking for $50.
We finally make it to the Nasdaq and everyone is so quite!
Did not think we would get below .3 again but it looks like it will without news this week.
We have that kind of potential here thats for sure. Just the small FDA obsticle now
Hopefully "we" will be rewarded. Ive been sooo patient with this. Seeing other companies I watch heading up is just killing me.
Anemic.
10Q is out and the debt is much improved. It may drive us down further still because it is still not 'pretty'
Another good day on small volume. This will get to $2 near term. Chart looking bullish
Moving up on low volume. Chart looks thin upto $2
SatCon Technology [SATC 1.18 -0.05 (-4.07%) ] is a clean energy technology provider of utility grade power solutions for the renewable energy market, primarily the large-scale commercial and utility-scale solar photovoltaic markets.
From a technical perspective, SATC is moving to the upside here right off some near-term support around $1 with above average volume. This move is quickly pushing the stock within range of triggering a near-term-breakout trade. That trade will hit once SATC manages to clear $1.36 with high volume.
Traders should now look for long-biased trades once SATC manages to sustain a move or close above $1.36 with volume that's near or above 159,897 shares. At last check, SATC has hit an intraday high of $1.27 and volume is a bit above its three-month average volume. If that breakout triggers soon, then look for SATC to retest or possibly take out its 50-day moving average of $1.71.
www.cnbc.com/id/48610692
Pretty sure unless we see updates next week we will see lower .30s
One of these big buyers last week will get nervous and sell off. Just be ready.
You sold railrider on the move up?
The earnings profit margin increase was significant. Headed in the right direction at least but still losing money.
It was a good piece of news this morning. It provided some insight on how the trials are going but did not generate any excitement
U.S. Highland partners with advanced electronic control systems
MENAFN - - 8/7/2012 1:58:01 PM
U.S. Highland partners with advanced electronic control systems
Aug 07, 2012 (TELECOMWORLDWIRE via COMTEX) -- Powertrain maker U.S. Highland UHLN has announced the formalization of a strategic partnership with NIRA Control AB, an international, state of the art technology corporation, located in Stockholm, Sweden, that specializes in development and delivery of custom made advanced electronic control units for combustion engine platforms.
"U.S. Highland and NIRA have assembled a team of experts for the customization of ECUs tailored specifically to U.S. Highland's powertrains, motorcycles, ATVs, and UTVs," said U.S. Highland's president and CEO John R. Fitzpatrick, III. "Results to date have been exceptional and are allowing each respective company to leverage capabilities that will enhance the entire industry," Fitzpatrick concluded.
U.S. Highland is now in great position for mass production of engine and vehicle platforms with anticipated production of select models in the fall of 2012. NIRA ECUs are exceptionally versatile and will allow U.S. Highland to offer its customers a wide array of products with very flexible high performance characteristics.
"The strategic relationship between NIRA and U.S. Highland is yet another example of our commitment to Stock Holders and Investors as well as to our expanding OEM American Made Performance products market," said Robert Harris, chairman of U.S. Highland. Harris continued by saying, "U.S. Highland and NIRA will continue to work as a strategic partnership to ensure high performance, cost effective, OEM products and services."
Comments on this story may be sent to tww.feedback@m2.com
http://www.menafn.com/menafn/d0bfe09f-a3fd-4d61-9d79-80df43408d7a/US-Highland-partners-with-advanced-electronic-control-systems?src=main